



**Date: 3 December 2019**

**Sydney, Australia**

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

**NOTICE UNDER SECTION 708A(5)(E) OF THE CORPORATIONS ACT 2001 (Cth)**

---

**Sydney, 2 December 2019:** Noxopharm Limited (ASX: NOX) (**Noxopharm** or the **Company**) has today issued 647,250 Ordinary Shares (**New Shares**) as per the attached Appendix 3B and these New Shares will rank equally in respects with existing ordinary shares.

The Company notes the ASX Release related to updated scientific results released concurrently with this Notice.

NOX gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

- 1 The New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
- 2 As at the date of this notice, NOX has complied with:
  - (a) The provisions of Chapter 2M of the Corporations Act as they apply to NOX; and
  - (b) Section 674 of the Corporations Act.
- 3 As at the date of this notice, there is no information that is “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

For and on behalf of the Board,

Yours faithfully,

A handwritten signature in blue ink, appearing to read "D. Franks", with a horizontal line underneath.

David Franks  
Company Secretary



### **About Noxopharm**

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda<sup>®</sup> and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.

### **About Veyonda<sup>®</sup>**

Veyonda<sup>®</sup> (previously known as NOX66) is a suppository dosage formulation of the experimental anti-cancer drug, idronoxil, that leads in the body to the formation of a proprietary pro-drug form. Idronoxil specifically inhibits the ability of cancer cells to respond to stress, such as that induced by radiation, leading to loss of pro-survival signaling via sphingosine-1-phosphate. Idronoxil also promotes the STING mechanism, thereby activating the body's innate immune system.

[www.noxopharm.com](http://www.noxopharm.com)

### **Investor & Corporate Enquiries**

#### **Media Contact Australia**

Prue Kelly

M: 0459 022 445

E: [Prue.Kelly@noxopharm.com](mailto:Prue.Kelly@noxopharm.com)

#### **Company Secretary:**

David Franks

T: +61 2 9299 9690

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

#### **Media Contact USA:**

Frank de Maria

Purposeful Communications

T: +1 347 647 0284

E: [frank.demaria@purposefulcommunications.com](mailto:frank.demaria@purposefulcommunications.com)

### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.